IL-10 is an anti-inflammatory cytokine that suppresses synthesis of proinflammatory cytokines and their receptors. Here we tested the possibility that TNFα-induced hormone resistance in myoblasts might be overcome by IL-10. We found that IL-10 restores myogenesis by suppressing the ability of exogenous TNFα to inhibit IGF-I-induced myogenin. This protection occurs without decreasing global activity of TNF receptors since IL-10 does not impair TNFα-induced IL-6 synthesis or ERK1/2 phosphorylation. Instead, IL-10 acts to prevent TNFα-induced phosphorylation of JNK. These findings demonstrate that IL-10 serves a previously unrecognized protective role in muscle progenitors by overcoming TNFα-induced resistance to IGF-I.
Introduction
It is now clear that cells of the immune system interact with muscle cells to regulate muscle development, including responses to injury and repair and a variety of dystrophies (Tidball, 2005) . The potential role of inflammation in muscle development was most recently shown in young dystrophic mice by depletion of neutrophils or by injections of Etanercept, a soluble TNF receptor antagonist (Hodgetts et al., 2006) : both treatments significantly reduced muscle necrosis. At the other end of the spectrum, prolonged elevations of proinflammatory cytokines are closely associated with muscle wasting that occurs during the sarcopenia of aging and in cachectic AIDS and cancer patients. These clinical disorders occur along with a decline in IGF-I anabolic activity, which is consistent with in vitro findings in muscle progenitor cells. Very low concentrations of TNFα (0.01-1 ng/ml) inhibit IGF-I-induced protein synthesis (Broussard et al., 2003; Strle et al., 2004) and expression of the critical muscle differentiation factors, MyoD (Strle et al., 2004) and myogenin (Broussard et al., 2003; Strle et al., 2004) . This ability of TNFα to induce hormone resistance is mediated by c-Jun N-terminal kinase (JNK) (Strle et al., 2006) . JNK is a stress-activated protein kinase (SAPK) that is implicated in the pathophysiology of major metabolic and inflammatory disorders mainly because it serves as a key signaling intermediate downstream of two major proinflammatory cytokine receptors, TNFα receptor (TNFR)1 and IL-1β receptor (Manning and Davis, 2003; Wajant and Scheurich, 2004) . Potential treatments that might overcome TNFα-induced hormone resistance in myoblasts are unknown. (2004-35206-14144 
